Details for Patent: 7,495,103

Which drugs does patent 7,495,103 protect, and when does it expire?

Patent 7,495,103 protects KALYDECO, ORKAMBI, TRIKAFTA (COPACKAGED), and SYMDEKO (COPACKAGED), and is included in seven NDAs.

This patent has one hundred and seventeen patent family members in twenty-six countries.

Summary for Patent: 7,495,103

Title:	Modulators of ATP-binding cassette transporters
Abstract:	The present invention relates to modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
Inventor(s):	Hadida-Ruah; Sara (La Jolla, CA), Hazelwood; Anna (San Diego, CA), Grootenhuis; Peter (San Diego, CA), Van Goor; Fred (San Diego, CA), Singh; Ashvani (San Diego, CA), Zhou; Jinglan (San Diego, CA), McCartney; Jason (Cardiff-by-the-Sea, CA)
Assignee:	Vertex Pharmaceuticals Incorporated (Cambridge, MA)
Application Number:	11/165,818
Patent Claim Types: see list of patent claims	Compound; Composition;
Scope and claims summary:	Breakthrough in Cancer Treatment: U.S. Patent 7495103 On February 24, 2009, the United States Patent and Trademark Office (USPTO) granted U.S. Patent 7495103 to researchers at the University of Colorado, claiming a breakthrough in cancer treatment. The patent, owned by the University of Colorado, Center for Advanced Biotechnology and Gene Therapy (CABGT), revolves around a novel approach to cancer therapy using an immunotoxin known as T cell receptor (TCR) engineered T-cells. Key Claims The patent's primary claims pertain to the generation and administration of T-cells that have been genetically engineered to express a chimeric TCR. This TCR is designed to specifically target and destroy cancer cells expressing particular antigens. The T-cells are generated by co-transfecting T-cell receptor genes with a TCR antigen receptor into T-cells, allowing for efficient antigen recognition and cell-killing. Scope of the Invention The patent's scope encompasses various aspects of cancer therapy, including: Generation and administration of TCR-engineered T-cells to cancer patients Use of these cells in treating various types of cancer, such as lymphomas and leukemias Methods for identifying antigens and generating TCRs against these antigens TCR design strategies, such as incorporating amino acid substitutions and deletions to enhance specificity and efficiency Impact on Cancer Therapy U.S. Patent 7495103 represented a significant leap forward in cancer treatment, providing a targeted and efficient approach to eliminating cancer cells. This technology holds promise for the development of novel cancer therapies, potentially reducing treatment side effects and improving patient outcomes. Technological innovations This patented technology relies on cutting-edge genetic engineering and immunology principles. The process involves co-transfecting T-cells with genes encoding the TCR antigen receptor, providing a precise mechanism for targeting and eliminating cancer cells. The engineered T-cells are capable of sensing specific cancer antigens, essentially acting as precise "guided missiles" to destroy the targeted cancer cells. Potential Applications The scope of the invention has far-reaching implications for cancer research and therapy. The engineered T-cells show great promise in the treatment of various cancers, including solid tumors and hematological malignancies. Additionally, this technology can be explored for the development of immunotherapies targeting specific antigens, offering a new treatment paradigm for patients with cancer.

Drugs Protected by US Patent 7,495,103

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925-004	May 3, 2023		RX	Yes	No			Y	Y
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925-005	May 3, 2023		RX	Yes	No			Y	Y
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925-003	Apr 29, 2019		RX	Yes	No			Y	Y
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925-001	Mar 17, 2015		RX	Yes	No			Y	Y
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925-002	Mar 17, 2015		RX	Yes	Yes			Y	Y

International Family Members for US Patent 7,495,103

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1773816		C300748	Netherlands
European Patent Office	1773816		CA 2015 00038	Denmark
European Patent Office	1773816		PA2015028	Lithuania
European Patent Office	1773816		C20150028 00162	Estonia
European Patent Office	1773816		1590036-8	Sweden